Evolution of structural rearrangements in prostate cancer intracranial metastases.

Recurrent somatic alterations in intracranial metastases did not reach statistical significance for enrichment and included TP53 mutation or deletion (8/10 samples, 7/9 patients with intracranial metastases versus 10/26 samples, 7/13 patients with other metastatic lesions), AR mutation (2 samples, 2 patients) and AR full or partial copy number gain (6 samples, 6 patients), FOXA1 mutation or gain (3 samples in 3 patients), homozygous or heterozygous deletion of PTEN (7 samples in 6 patients), and SKI (4 samples, 3 patients).

also in 111,027 other papers